The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Trigg, Ricky M and Lee, Liam and Prokoph, Nina and Jahangiri, Leila and Reynolds, C. Patrick and Burke, G. A. Amos and Probst, Nicola A and Han, Miaojun and Matthews, Jamie and Kai Lim, Hong and Manners, Eleanor and Martinez, Sonia and Pastor, Joaquin and Blanco-Aparicio, Carmen and Merkel, Olaf and Garces de los Fayos Alonso, Ines and Kodajova, Petra and Tangermann, Simone and Högler, Sandra and Luo, Ji and Kenner, Lukas and Turner, Suzanne D (2019) The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature communications, 10. ISSN 2041-1723

[img]
Preview
Text
s41467-019-13315-x.pdf - Published Version

Download (1MB)

Abstract

Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance mechanisms in ALK-positive neuroblastoma (NB), we herein employ genome-wide CRISPR activation screens of NB cell lines treated with brigatinib or ceritinib, identifying PIM1 as a putative resistance gene, whose high expression is associated with high-risk disease and poor survival. Knockdown of PIM1 sensitizes cells of differing MYCN status to ALK inhibitors, and in patient-derived xenografts of high-risk NB harboring ALK mutations, the combination of the ALK inhibitor ceritinib and PIM1 inhibitor AZD1208 shows significantly enhanced anti-tumor efficacy relative to single agents. These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.

Item Type: Article
Identification Number: https://doi.org/10.1038/s41467-019-13315-x
Date: 28 November 2019
Uncontrolled Keywords: Cancer models, Cancer therapeutic resistance, Paediatric cancer, Targeted therapies
Subjects: A100 Pre-clinical Medicine
Divisions: Faculty of Health, Education and Life Sciences > School of Health Sciences
Depositing User: Leila Jahangiri
Date Deposited: 07 Jan 2020 13:02
Last Modified: 12 Feb 2020 11:33
URI: http://www.open-access.bcu.ac.uk/id/eprint/8672

Actions (login required)

View Item View Item

Research

In this section...